5604 results
Refine Your Search
Enhancing the cytotoxicity of T cells in NRAS; ASXL1-AML through combined inhibition of MEK and HDACs
Acute myeloid leukemia (AML) is a heterogeneous malignant blood cancer. Its treatment outcome is influenced by the mutations. Oncogenic NRAS mutation…
Leveraging p53 to Improve Menin Inhibition in Leukemia Therapy
Acute myeloid leukemia remains a highly lethal disease. Menin inhibitors are an exciting new class of drugs in leukemic but are rarely curative and ha…
Subha Saha
Subha was born and raised in India where he completed his Masters in Biochemistry from the University of Calcutta, India. Thereafter, he joined the Ph…
The Role of TP53 in Mutant U2AF1 Myelodysplastic Syndromes
This project aims to understand why splicing factor gene mutations paradoxically impair the growth of hematopoietic progenitors. We will use mouse com…
Stefan Tarnawsky
Stefan Tarnawsky, M.D.; Ph.D. is a Hematology/Oncology fellow and junior physician scientist at the Washington University School of Medicine in Saint …
The PRMT5-p53-DUSP6 Axis: Integral Regulators of Cytokine Signaling in Hematopoietic Cells and AML Oncogenesis
This research investigates how the PRMT5-p53-DUSP6 axis regulates cytokine signaling in hematopoietic stem cells and its implications for AML (acute m…
Revisiting splicing factor mutations in MDS/AML – delving deep and wide
This project aims to uncover how obligatory heterozygous mutant splicing factors (SF) impact their wildtype counterparts’ functions, RNA interaction s…
.jpeg?v=12803026-5a5b-4485-934c-e19d3c62e8d1&crop=true&keep=c&w=400&h=400)
Hannah Maul-Newby
I received my BS in biochemistry from Gonzaga University and my PhD in Molecular, Cell and Developmental Biology under the guidance of Dr. Melissa Jur…
Affinity-Tuned T-Cell Engagers for Dual Targeting of B-Myeloid Mixed Phenotype Acute Leukemia
Our objective is to develop a highly specific engaging therapy to treat a subtype of leukemia that currently lacks effective treatment. We also aim t…
Mignon Loh
Dr. Loh is a Professor of Pediatrics at the University of Washington and Seattle Children’s Hospital. She is the Division Head of Hematology, Oncology…
Novel therapeutic strategies to improve the outcomes of patients with myeloproliferative neoplasms
The identification of critical therapeutic targets in myeloproliferative neoplasm (MPN) cells will have a significant impact on the development of muc…
Gary Reuther
Gary Reuther, PhD (Professor in the Departments of Molecular Oncology and Malignant Hematology at the Moffitt Cancer Center) earned his PhD from Duke …
Optimized, computationally engineered CD70-targeting CAR-T cells for high-risk multiple myeloma
Despite an array of promising immunotherapies, the blood cancer multiple myeloma still remains without any known cure. Patients with disease in parti…
.jpg?v=82bb5927-060a-4c7e-ac2b-132bf54543f9&crop=true&keep=c&w=400&h=400)
Arun Wiita
Dr. Arun Wiita is a and Associate Professor in the Dept. of Laboratory Medicine and Dept. of Bioengineering & Therapeutic Sciences at the University …
β-Hydroxybutyrate To Enhance CAR T Cell Immunotherapy Against Hematological Cancers
This project aims to enhance CAR therapy, a promising treatment for blood cancers, by leveraging the ketogenic diet and its key byproduct, (BHB). We…
Rational repurposing effort to disrupt beta-catenin protein degradation in B-cell malignancies
While forms transcriptional complexes to activate and proliferation in other cell types, our studies in cells revealed repressive complexes to sup…
Markus Muschen
Markus Müschen, , is a at Yale University, where he serves as the Director of the Center of Molecular and Cellular Oncology and Chief of the Division…
Gene-edited CD19 CAR-T cells with superior proliferation, persistence and serial-killing activity
A therapy for blood cancers reprograms a patient’s T cells to kill tumor cells. This treatment, called cell therapy, can work well, but the often r…
Joseph Tuscano
In , I began as an academic physician at UC Davis. I developed a productive, independent research program, and as the Director of Hematologic Maligna…
Michael Girardi
The in his family to attend college, Dr. Girardi is the Evans Professor of Dermatology and Vice Chair of Faculty Development & Scientific Innovation …
Personalized Anti-TCRVbeta2 therapeutic antibody and ADC for T Cell Leukemias and Lymphomas
T cell cancers together comprise ~% of acute leukemias and 's lymphomas. A major challenge with currently available treatments for these is that the t…
Shih-Shih Chen
My lab focuses on the tumor microenvironment as a risk factor for chronic lymphocytic leukemia (CLL) and Richter's transformation (RT). We develop the…
Targeting TLR9 Signaling to restore immunomodulating function of FRCs in Richter's Transformation
Richter’s transformation (RT) refers to the development of an aggressive lymphoma in patients with a prior diagnosis of chronic lymphocytic leukemia (…
Understanding and targeting rare Ag–(CD19/CD20–) Follicular Lymphoma cells to prevent post-immunotherapy antigen escape
Follicular lymphoma (FL) affects ~, Americans and is, unfortunately, frequently referred to as incurable, however, that may change in the near future.…
Joshua Brody
Dr. Brody is Director of the Lymphoma Immunotherapy Program at Mount Sinai and a member of the Depart of Immunology.